148 related articles for article (PubMed ID: 16011584)
1. Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age?
Rivard GE; Lillicrap D; Poon MC; Demers C; Lépine M; St-Louis J; Warner M
Haemophilia; 2005 Jul; 11(4):335-9. PubMed ID: 16011584
[TBL] [Abstract][Full Text] [Related]
2. Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia.
Baudo F; de Cataldo F; Gaidano G;
Haematologica; 2004 Jun; 89(6):759-61. PubMed ID: 15194550
[TBL] [Abstract][Full Text] [Related]
3. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
Brenner B; Wiis J
Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
[TBL] [Abstract][Full Text] [Related]
4. Management of oral bleedings with recombinant factor VIIa in children with haemophilia A and inhibitor.
Laguna P; Klukowska A
Haemophilia; 2005 Jan; 11(1):2-4. PubMed ID: 15660981
[TBL] [Abstract][Full Text] [Related]
5. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors.
Schneiderman J; Nugent DJ; Young G
Haemophilia; 2004 Jul; 10(4):347-51. PubMed ID: 15230948
[TBL] [Abstract][Full Text] [Related]
6. Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy.
Petrini P; Klementz G
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S143-6. PubMed ID: 9819046
[TBL] [Abstract][Full Text] [Related]
7. The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa.
Negrier C; Hay CR
Semin Thromb Hemost; 2000; 26(4):407-12. PubMed ID: 11092216
[TBL] [Abstract][Full Text] [Related]
8. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
[TBL] [Abstract][Full Text] [Related]
9. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII.
Liebman HA; Chediak J; Fink KI; Galvez AG; Shah PC; Sham RL
Am J Hematol; 2000 Mar; 63(3):109-13. PubMed ID: 10679799
[TBL] [Abstract][Full Text] [Related]
10. Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice.
Ovlisen K; Kristensen AT; Valentino LA; Hakobyan N; Ingerslev J; Tranholm M
J Thromb Haemost; 2008 Jun; 6(6):969-75. PubMed ID: 18363814
[TBL] [Abstract][Full Text] [Related]
11. Combination of FVIII and low-dose rFVIIa improves haemostasis in acquired haemophilia A patients: a collaborative controlled study.
Zhang XH; Zhu XL; Niu T; Sun J; Liu H; Feng R; Yang LH; Wei Q; Ma QH; Wang QM; Feng FE; Fu HX; Mo XD; Lv M; Huang XJ
Thromb Res; 2015 May; 135(5):835-40. PubMed ID: 25747536
[TBL] [Abstract][Full Text] [Related]
12. Emerging off-label uses for recombinant activated factor VII: grading the evidence.
Enomoto TM; Thorborg P
Crit Care Clin; 2005 Jul; 21(3):611-32. PubMed ID: 15992675
[TBL] [Abstract][Full Text] [Related]
13. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
[TBL] [Abstract][Full Text] [Related]
14. Effective and safe use of recombinant factor VIIa (NovoSeven) in elderly mild haemophilia A patients with high-titre antibodies against factor VIII.
Leebeek FW; Kappers-Klunne MC; Jie KS
Haemophilia; 2004 May; 10(3):250-3. PubMed ID: 15086322
[TBL] [Abstract][Full Text] [Related]
15. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
[TBL] [Abstract][Full Text] [Related]
16. Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors.
Schmidt ML; Gamerman S; Smith HE; Scott JP; DiMichele DM
Am J Hematol; 1994 Sep; 47(1):36-40. PubMed ID: 8042614
[TBL] [Abstract][Full Text] [Related]
17. Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A.
Lisman T; de Groot PG; Lambert T; Røjkjaer R; Persson E
J Thromb Haemost; 2003 Oct; 1(10):2175-8. PubMed ID: 14521601
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany.
Auerswald G; von Depka Prondzinski M; Ehlken B; Kreuz W; Kurnik K; Lenk H; Scharrer I; Schramm W; Zimmermann R
Haemophilia; 2004 Sep; 10(5):499-508. PubMed ID: 15357777
[TBL] [Abstract][Full Text] [Related]
19. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
[TBL] [Abstract][Full Text] [Related]
20. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor.
Stewart AJ; Hanley JP; Ludlam CA
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S93-5. PubMed ID: 9819036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
